Claims for Patent: 5,264,446

Summary for Patent: 5,264,446

Title:	Solid medicament formulations containing nifedipine, and processes for their preparation
Abstract:	The invention is directed to the provision of solid pharmaceutical compositions (and methods for their preparation) containing nifidipine crystals with a specific surface area of 1.0 to 4.0 m.sup.2 /g., in admixture with a solid diluent. The said compositions overcome the deficiencies of prior art compositions containing nifidipine, which is known to have effect as a coronary vasodilator.
Inventor(s):	Hegasy; Ahmed (Leverkusen, DE), Ramsch; Klaus-Dieter (Heerlen, NL)
Assignee:	Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:	07/892,439
Patent Claims:	1. A solid pharmaceutical composition comprising as the active ingredient an effective amount of nifedipine crystals with a specific surface area of 1.0 to 4 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 2. A solid medicament in dosage unit form comprising an effective amount of nifedipine crystals with a specific surface area of 1.0 to 4 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 3. A medicament in the form of tablets, pills, dragees, capsules, suppositories, sachets or two-layer tablets comprising an effective amount of nifedipine crystals with a specific surface area of 1.0 to 4 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 4. In a method for treating hypertension by administering an effective amount therefor of nifedipine crystals to a patient, the improvement comprising employing nifedipine crystals having a specific surface area of 1.0 to 4 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 5. A solid pharmaceutical composition comprising as the active ingredient an effective amount of nifedipine crystals with a specific surface area of about 1.2 to 3.6 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 6. A solid medicament in dosage unit form comprising an effective amount of nifedipine crystals with a specific surface area of about 1.2 to 3.6 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 7. A medicament in the form of tablets, pills, dragees, capsules, suppositories, sachets or two-layer tablets comprising an effective amount of nifedipine crystals with a specific surface are of about 1.2 to 3.6 m.sup.2 /g, in admixture with a solid diluent, to result in sustained release of nifedipine. 8. In a method for treating hypertension by administering an effective amount therefor of nifedipine crystals to a patient, the improvement comprising employing nifedipine crystals having a specific surface area of about 1.2 to 3.6 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 9. A solid pharmaceutical composition comprising as the active ingredient an effective amount of nifedipine crystals with a specific surface area of 1.3 to 3.1 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 10. A solid medicament in dosage unit form comprising an effective amount of nifedipine crystals with a specific surface area of 1.3 to 3.1 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine. 11. A medicament in the form of tablets, pills, dragees, capsules, suppositories, sachets or two-layer tablets comprising an effective amount of nifedipine crystals with a specific surface area of 1.3 to 3.1 m.sup.2, in admixture with a solid diluent, to result in a sustained release of nifedipine. 12. In a method for treating hypertension by administering an effective amount therefor of nifedipine crystals to a patient, the improvement comprising employing nifedipine crystals having a specific surface area of 1.3 to 3.1 m.sup.2 /g, in admixture with a solid diluent, to result in a sustained release of nifedipine.